Market Research Logo

Global Gaucher Disease Market 2015-2019

Global Gaucher Disease Market 2015-2019

About Gaucher Disease

Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities.

TechNavio's analysts forecast the Global Gaucher Disease market to grow at a CAGR of 7.60 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Gaucher Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes:

  • Enzyme replacement therapy
  • Substrate reduction therapy
Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments:
  • Biologics
  • Small Molecules
Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments:
  • Oral
  • Parenteral
Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments:
  • Solid
  • Liquid
TechNavio's report, Global Gaucher Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gaucher Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
  • Americas
  • APAC
  • EMEA
Key Vendors
  • Actelion Pharmaceuticals
  • Genzyme
  • Pfizer
  • Shire
Other Prominent Vendors
  • Amicus Therapeutics
  • Belrose Pharma
  • Bionaturis
  • Biosidus
  • ISU Abxis
  • JCR Pharmaceuticals
  • LIXTE Biotechnology
  • Neuraltus Pharmaceuticals
  • Protalix BioTherapeutics
  • Teva Pharmaceuticals
  • UCB
  • Utrecht Holdings
  • Zywie
  • Market Driver
  • Special Provisions for Orphan Drugs
  • For a full, detailed list, view our report
  • Market Challenge
  • Limited Patient Population
  • For a full, detailed list, view our report
  • Market Trend
  • Regulatory Assistance in Emerging Nations
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global Gaucher Disease Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Gaucher Disease Market: Actelion Pharmaceuticals Ltd., Genzyme Corp., Pfizer Inc. and Shire plc

Other Prominent Vendors in the market are: Amicus Therapeutics, Belrose Pharma, Bionaturis, Biosidus, ISU Abxis, JCR Pharmaceuticals, LIXTE Biotechnology, Neuraltus Pharmaceuticals, Protalix BioTherapeutics, Teva Pharmaceuticals, UCB and Utrecht Holdings.

Commenting on the report, an analyst from TechNavio’s team said: “One key trend upcoming in this market is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area.”

According to the report, the special provisions offered to drugs for orphan diseases such as Zavesca and Cerezyme is the major contributor to the market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to the vendors for conducting research in this area.

Further, the report states that one of the main challenges that the market faces is the limited patient population. Limited availability of treatment groups prolong the time period during which the vendor can recover R&D expenses of the drug. The restricted patient population also hinders effective evaluation of drugs based on clinical trials.

Companies Mentioned

Actelion Pharmaceuticals, Genzyme, Pfizer, Shire, Amicus Therapeutics, Belrose Pharma, Bionaturis, Biosidus, ISU Abxis , JCR Pharmaceuticals , LIXTE Biotechnology , Neuraltus Pharmaceuticals, Protalix BioTherapeutics, Teva Pharmaceuticals, UCB,Utrecht Holdings, Zywie

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
      • Table Snapshot of Gaucher Disease
      • Types of Gaucher Disease
        • Table Types of Gaucher Disease
      • Symptoms
      • Diagnosis
    • Etiology
      • Table Heredogram of Inheritance Pattern for Gaucher Disease
    • Epidemiology
    • Clinical Manifestations
      • Table Clinical Manifestations of Gaucher Disease
    • Management
      • Enzyme Replacement Therapy
      • Substrate Reduction Therapy
    • Economic Burden
      • Table Snapshot of Economic Burden of Gaucher Disease
  • Pipeline Analysis
    • Table Clinical Trials by Status (as of February 2015)
    • Table Clinical Trials by Phase (as of February 2015)
  • Market Landscape
    • Market Overview
      • Table Snapshot of Global Gaucher Disease Market 2014
    • Market Size and Forecast
      • Table Global Gaucher Disease Market 2014-2019 (US$ million)
      • Table Drivers and Challenges of Global Gaucher Disease Market
    • Five Forces Analysis
  • Market Segmentation by Type of Therapy
    • Table Segmentation of Global Gaucher Disease Market by Type of Therapy
    • Enzyme Replacement Therapy
    • Substrate Reduction Therapy
      • Table Segmentation of Global Gaucher Disease Market by Type of Therapy 2014
  • Market Segmentation by Type of Molecule
    • Table Segmentation of Global Gaucher Disease Market by Type of Molecule
    • Biologics
    • Small Molecules
      • Table Segmentation of Global Gaucher Disease Market by Type of Molecule 2014
  • Market Segmentation by Route of Administration
    • Table Segmentation of Global Gaucher Disease Market by Route of Administration
    • Oral
    • Parenteral
      • Table Segmentation of Global Gaucher Disease Market by Route of Administration 2014
  • Market Segmentation by Dosage Form
    • Table Segmentation of Global Gaucher Disease Market by Dosage Form
    • Solid
    • Liquid
      • Table Segmentation of Global Gaucher Disease Market by Dosage Form 2014
  • Geographical Segmentation
    • Table Segmentation of Global Gaucher Disease Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Global Gaucher Disease Market Share Analysis 2014
      • Genzyme
        • Table Genzyme: Product Portfolio
        • Table Cerezyme: SWOT Analysis
        • Table Cerdelga: SWOT Analysis
      • Shire
        • Table Shire: Product Portfolio
        • Table Vpriv: SWOT Analysis
      • Actelion Pharmaceuticals
        • Table Actelion Pharmaceuticals: Product Portfolio
        • Table Zavesca: SWOT Analysis
      • Pfizer
        • Table Pfizer: Product Portfolio
        • Table Elelyso: SWOT Analysis
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • Actelion Pharmaceuticals
      • Key Facts
      • Business Overview
      • Geographical Segmentation 2013
        • Table Actelion Pharmaceuticals: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Genzyme
      • Key Facts
      • Business Overview
      • Product Segmentation by Revenue 2013
        • Table Genzyme: Product Segmentation by Revenue 2013
      • Product Segmentation by Revenue 2012 and 2013
        • Table Genzyme: Product Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation
        • Table Genzyme: Geographical Segmentation
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Pfizer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Pfizer: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Pfizer: Business Segmentation by Revenue 2012 and 2013
      • Geographical Segmentation by Revenue
        • Table Pfizer: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Shire
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Shire: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report